An American Biotechnology company, with the name Moderna, has announced that its COVID-19 vaccine could be up to 94.5 per cent effective, though it would seek approval of the Food and Drug Administration (FDA) to roll out the vaccine for immunization.
The Company made the announcement in a press statement, stating that after its phase 3 trial, the vaccine met statistical criteria with an efficacy rate of 94.5 percent.
According to agency report from News Agency of Nigeria, the news is coming a week after another U.S. drug maker, Pfizer, announced the development of a vaccine with 90 per cent effectiveness.
“Experts are warning that the numbers are not conclusive, as both estimates could increase or decrease as trial continues. The application, to be made in the coming weeks, would include at least two months of safety data after the last injection in half the volunteers.”
The organization added that the FDA application would include the final analysis” of 151 cases of COVID-19 in its trial, rather than just the initial 95 cases.
Moderna is expected to have 20 million doses to go along with Pfizer’s 50 million for global distribution before more can be made in 2021.